Losing Coverage Is Stressful — But You Have a Plan
If your insurance just stopped covering your GLP-1, the first feeling is usually panic about the price tag. Take a breath. There are well-worn, legitimate paths to keep your medication affordable, and millions of people are walking them right now. You don't have to figure this out alone, and you don't have to quit.
We've laid out the five cheapest routes below, roughly in order of cost, with the honest trade-offs for each. The right one for you depends on your insurance status, your diagnosis, and your comfort with compounded products — so think of this as a menu to discuss with your prescriber, not a one-size-fits-all answer.
The Scale of the Problem
You're not imagining how widespread this is. Coverage losses hit an estimated 41 million commercially insured Americans in 2026, as insurers like CVS Caremark dropped Zepbound and others restricted Wegovy. That's a sweeping change, driven by the high cost of these drugs at scale.
Knowing the scale helps in two ways. It reframes your situation as a systemic shift rather than a personal setback, and it explains why so many affordable alternatives have emerged — providers and manufacturers are competing hard for the huge number of newly cash-pay patients.
The 5 Cheapest Options, Explained
In rough order of cost: First, manufacturer savings cards — the lowest if you qualify (sometimes as little as $25), but generally limited to commercially insured patients. Second, compounded semaglutide or tirzepatide near $99, which gives you the same molecule for a fraction of the price, with the trade-off that it isn't FDA-approved.
Third, the new oral pill around $149 — FDA-approved and needle-free, a nice middle ground. Fourth, the diabetes-labeled product (like Mounjaro) for those with a type 2 diabetes diagnosis, which can be better covered. Fifth, self-pay vials around $349 — the FDA-approved cash-pay option when nothing cheaper applies.
| Option | Approx. Cost/Month |
|---|---|
| Manufacturer savings card | From $25 (if eligible) |
| Compounded semaglutide / tirzepatide | $99 |
| Oral GLP-1 pill | $149 |
| Diabetes-labeled product | Varies |
| Self-pay vials | $349 |
Cheapest routes after losing coverage (seed data — please verify before relying on it)
How to Choose the Right One
Start with eligibility, because it narrows the list fast. Savings cards and diabetes-label routes depend on your diagnosis and insurance — if you have commercial coverage and qualify, the savings card is hard to beat; if you have diabetes, the Mounjaro route may shine. If those doors are closed, you're choosing among compounded options, oral pills, and self-pay vials.
From there, weigh price against your comfort level. Compounded options are cheapest but not FDA-approved; the oral pill and self-pay vials cost more but carry FDA approval. There's no wrong answer here — only the one that fits your budget and your peace of mind. Your prescriber can help you land on it.
Bridge, Don't Stop
The most important advice we can give: don't let a coverage loss turn into stopping cold. Even a temporary, cheaper bridge protects the progress you've made, because stopping abruptly tends to bring appetite and weight back.
Move quickly to avoid a long gap, loop in your prescriber, and pick the most affordable route you can sustain for now. Coverage and pricing keep shifting in 2026, so today's bridge might give way to a better option in a few months. Staying on treatment is what matters.